BRCA1 and hyperinsulinemic hypoglycemia, familial, 4: The PARP inhibitor olaparib has a more obvious effect on patients with BRCA1 deficiency in the treatment of breast cancer, but patients with BRCA1 deficiency account for only a part of the population [45,46,47].